Q32 Bio Inc. QTTB
Q32 Bio Inc. (Nasdaq: QTTB) is an immunology/inflammation drug developer. Its lead program, bempikibart (ADX-914), is in Phase 2 for Alopecia areata.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| bempikibart (ADX-914), anti-IL-7Ralpha | Alopecia areata (SIGNAL-AA Part A and Part B, Phase 2a) | antibody | Phase 2 |
| bempikibart (ADX-914) | Atopic dermatitis (SIGNAL-AD Phase 2a; primary endpoint missed in Part B) | antibody | Phase 2 |
Recent results and decisions
- Jul 13, 2026positive Positive 36-week topline: mean SALT reduction 35.3% (mITT); SALT-20 in 40.0% (10/25) mITT and 30.3% (10/33) ITT; no treatment-related SAEs or Grade>=3 AEs (open-label, n=33).
Mean percent reduction in SALT score from baseline of 35.3% in the mITT analysis.
Filing - May 5, 2026started First patient dosed in the open-label extension of SIGNAL-AA Part B.
The first patient has been dosed in the OLE portion of Part B.
Filing - Nov 13, 2025completed enrollment Completed enrollment in Part B of the Phase 2a SIGNAL-AA trial, increasing size to 33 patients.
Completed enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial and increased the trial size to 33 patients based on patient demand, with topline data readout expected in mid-2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.